



# Medi-Cal Rx Monthly Bulletin

October 1, 2021

The monthly bulletin consists of alerts and notices posted to the [Bulletins & News](#) page on the Medi-Cal Rx Web Portal. Sign up for the [Medi-Cal Rx Subscription Service](#) to be notified when new information is posted.

- [Changes to the Contract Drugs List \(CDL\), Effective October 1, 2021](#)
- [Changes to the Contract Drugs List \(CDL\) – Over the Counter Drugs, Effective October 1, 2021](#)
- [Changes to the Contract Drugs List \(CDL\) – Authorized Drug Manufacturer Labeler Codes, Effective October 1, 2021](#)
- [Updated Medi-Cal Rx NCPDP Payer Specification Sheet Now Available](#)
- [Changes to the Family PACT Pharmacy Formulary](#)
- [Medi-Cal Rx Electronic Claims Submission](#)

## 1. Changes to the Contract Drugs List (CDL), Effective October 1, 2021

The below changes have been made to the Contract Drugs List, effective October 1, 2021.

For more information, see the [Contract Drugs List](#) on the Medi-Cal Rx Web Portal.

Drug Name	Description	Effective Date
Aprepitant	Labeler code restriction (00006) removed.	October 1, 2021
Bismuth Subcitrate Potassium/Metronidazole/ Tetracycline HCL	Added to CDL with a restriction.	October 1, 2021
Clarithromycin	Date of service restriction ( <b>November 1, 2021</b> ) for the extended-release tablets. Will be moved to outdated section after this date.	October 1, 2021
COVID-19 Vaccine	Added to CDL with restrictions.	October 1, 2021

Drug Name	Description	Effective Date
Deutetrabenazine	Added to CDL with restrictions.	October 1, 2021
Didanosine	Date of service restriction ( <b>November 1, 2021</b> ) for the capsules, delayed release, E.C. Will be moved to outdated section after this date.	October 1, 2021
Encorafenib	Date of service restriction ( <b>November 1, 2021</b> ) for the 50 mg capsules. Will be moved to outdated section after this date.	October 1, 2021
Infigratinib	Added to CDL with restrictions.	October 1, 2021
Insulin Glargine (rDNA Origin)	Additional labeler code (49502) added to labeler restriction.	October 1, 2021
Leuprolide Acetate (Fensolvi®)	Added to CDL with restrictions.	October 1, 2021
Leuprolide Acetate (Eligard®)	Added to CDL with restrictions.	October 1, 2021
Levonorgestrel and Ethinyl Estradiol	Patches added to CDL with restrictions.	October 1, 2021
Loncastuximab Tesirine-LPYL	Added to CDL with restrictions.	October 1, 2021
Olaratumab	Date of service restriction ( <b>November 1, 2021</b> ). Will be moved to outdated section after this date.	October 1, 2021
Omeprazole/Amoxicillin/Rifabutin	Added to CDL with a restriction.	October 1, 2021
Somatropin	Added to CDL with restrictions.	October 1, 2021
Sorafenib	Labeler code restriction (50419) removed.	October 1, 2021

## 2. Changes to the Contract Drugs List (CDL) – Over the Counter Drugs, Effective October 1, 2021

The below changes have been made to the Contract Drugs List – Over the Counter Drugs, effective October 1, 2021.

For more information, see the [Contract Drugs List – Over the Counter Drugs](#) on the Medi-Cal Rx Web Portal.

Drug Name	Description	Effective Date
Acetaminophen	Suppositories (80 mg, 120 mg, 325 mg) added.	October 1, 2021

## 3. Changes to the Contract Drugs List (CDL) – Authorized Drug Manufacturer Labeler Codes, Effective October 1, 2021

The below changes have been made to the Contract Drugs List – Authorized Drug Manufacturer Labeler Codes, Effective October 1, 2021.

For more information, see the [Contract Drugs List – Authorized Drug Manufacturer Labeler Codes](#) on the Medi-Cal Rx Web Portal.

### Labeler Code Additions:

NDC Labeler Code	Contracting Company's Name	Effective Date
65038	CORIUM, INC.	October 1, 2021
71921	FLORIDA PHARMACEUTICAL PRODUCTS, LLC	October 1, 2021
72664	VGYAAN PHARMACEUTICALS	October 1, 2021
72730	QED THERAPEUTICS, INC.	October 1, 2021
73059	SHIELD THERAPEUTICS	October 1, 2021
73317	AUM PHARMACEUTICALS	October 1, 2021
73606	APL SALES I LLC	October 1, 2021
73607	AMIVAS (US), LLC	October 1, 2021

NDC Labeler Code	Contracting Company's Name	Effective Date
74528	ALBIREO PHARMA, INC.	October 1, 2021
75788	SCYNEXIS, INC.	October 1, 2021
78206	ORGANON LLC	October 1, 2021
79802	KADMON PHARMACEUTICALS, LLC	October 1, 2021
81561	PORTON BIOPHARMA LIMITED	October 1, 2021

**Labeler Code Terminations:**

NDC Labeler Code	Contracting Company's Name	Effective Date
66621	RARE DISEASE THERAPEUTICS, INC.	October 1, 2021
70720	TERSERA THERAPEUTICS LLC	October 1, 2021
89141	MIDATECH PHARMA US INC.	October 1, 2021

## 4. Updated Medi-Cal Rx NCPDP Payer Specification Sheet Now Available

### Medi-Cal Rx

Effective January 1, 2022, Magellan Medicaid Administration, Inc. (MMA) will be the new Medi-Cal Rx vendor. All administrative services related to Medi-Cal pharmacy benefits billed on pharmacy claims from the existing intermediaries, Medi-Cal Fee-for-Service (FFS) or Managed Care Plans (MCPs), will transition to MMA.

### Medi-Cal Rx NCPDP Payer Specification Sheet

In anticipation of this transition, an updated Medi-Cal Rx NCPDP Payer Specification Sheet is now available under [Forms and Information](#) on the Medi-Cal Rx Web Portal. The Medi-Cal Rx NCPDP Payer Specification Sheet includes the claim submission, prior authorization submission, eligibility verification request, and drug inquiry pricing request fields and requirements to submit Medi-Cal pharmacy transactions on or after January 1, 2022. The Medi-Cal Rx NCPDP Payer Specification Sheet also includes updated contact information. Pharmacy providers and their billing agents can use this information to make changes to their processes and technical solutions.

## 5. Changes to the Family PACT Pharmacy Formulary

The below changes have been made to the Family PACT Pharmacy Formulary, effective October 1, 2021.

For more information, see the [Family PACT Pharmacy Formulary](#) on the Medi-Cal Rx Web Portal.

Drug Name	Description	Effective Date
Levonorgestrel and Ethinyl Estradiol	Transdermal patches added with quantity limit restrictions.	October 1, 2021

## 6. Medi-Cal Rx Electronic Claims Submission

Beginning January 1, 2022, Magellan Medicaid Administration, Inc. (MMA) will provide administrative support and services for the Department of Health Care Services (DHCS) Medi-Cal Fee-for-Service (FFS) pharmacy benefits, collectively referred to as "Medi-Cal Rx." Medi-Cal Rx will include all pharmacy benefits billed by pharmacy providers on pharmacy claims for Medi-Cal beneficiaries in both the Medi-Cal FFS and managed care delivery systems.

Under the existing processes, Medi-Cal providers choosing to submit claims electronically to the Medi-Cal FFS Fiscal Intermediary (FI) must complete and submit the [DHCS 6153 \(Rev. 08/19\) form](#) titled "MEDI-CAL TELECOMMUNICATIONS PROVIDER AND BILLER APPLICATION/AGREEMENT." The DHCS 6153 form indicates that Medi-Cal providers will be provided a unique Medi-Cal Submitter Identification (ID) and password to be used for claims certification purposes, accuracy and correction of claims or payments, and more.

In order to reduce the burden on existing Medi-Cal pharmacy providers and ease the transition to Medi-Cal Rx, as well as to comply with the Governor's January 1, 2019 [Executive Order N-01-19](#), DHCS will be using the existing DHCS 6153 forms already on file for Medi-Cal pharmacy providers and billers submitting Medi-Cal Rx electronic claims until further notice.

For Medi-Cal Rx electronic claims submissions, Medi-Cal pharmacy providers will be provided specific Medi-Cal Rx credentials, which are different than the Medi-Cal Submitter ID and the password used for the existing Medi-Cal FFS FI. Please note that the use of unique Medi-Cal Rx credentials constitutes the acceptance of all terms and conditions outlined in the existing DHCS 6153 form.

While DHCS recognizes that the DHCS 6153 form only references the current Medi-Cal FFS FI, a new form that specifically references MMA and Medi-Cal Rx, inclusive of all related processes and procedures, is being developed. Medi-Cal Rx aims to release this new form no later than October 15, 2021. At that time, the Medi-Cal pharmacy provider/biller will need to return the new DHCS form within a specified time frame to ensure that an up-to-date Medi-Cal Rx-inclusive agreement is on file.

Until then, the provider/biller agrees that submission of electronic claims using the [Medi-Cal Rx NCPDP Standard Payer Sheet](#) will identify the submitter and shall serve as acceptance to the terms and conditions of DHCS' Medi-Cal Telecommunications Provider and Biller Application/Agreement (DHCS 6153). The provider/biller further acknowledges the necessity of maintaining the privacy of the Medi-Cal Rx credentials and agrees to bear full responsibility for the use or misuse of the Medi-Cal Rx credentials should privacy not be maintained.

If Medi-Cal pharmacy providers/billers have questions regarding this alert, please direct all such communications to the Medi-Cal Rx Customer Service Center by one of the available "Contact Us" options on the [Medi-Cal Rx Web Portal](#) or to the following mailing address:

Medi-Cal Rx Customer Service Center  
ATTN: Billing Agreement Processing  
P.O. Box 610  
Rancho Cordova, CA 95741-0610